natgillin/translations-raw huggingface dataset:
Because alendronic acid and vitamin D3 are already used separately in authorised medicines in the European Union (EU), the company presented data obtained in earlier studies and from the published literature from women who had been through the menopause and who were taking alendronic acid and vitamin D as separate tablets. 
Ker se alendronska kislina in vitamin D3 ločeno že uporabljata v zdravilih, odobrenih v Evropski uniji (EU), je družba predložila podatke iz starejših študij ter iz objavljene literature o ženskah, ki so že prestale menopavzo in so jemale alendronsko kislino in vitamin D kot ločeni tableti.
What benefit has Fosavance shown during the studies? 
Kakšne koristi je zdravilo Fosavance izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Fosavance. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight, it is included in Fosavance. 
Ker bolnice z osteoporozo z izpostavljanjem sončni svetlobi morda ne dobijo dovolj vitamina D3, je ta vključen v zdravilo Fosavance.
It slows the action of the osteoclasts, the cells that are involved in breaking down the bone tissue. 
Zavira delovanje osteoklastov, tj. celic v telesu, ki sodelujejo pri razgradnji kostnega tkiva.
The information presented by the company from earlier studies and the published literature showed that the dose of alendronic acid included in Fosavance was the same as the dose needed to prevent bone loss. 
Podatki iz starejših študij in objavljene literature, ki jih je predstavila družba, so pokazali, da je odmerek alendronske kisline v zdravilu Fosavance enak odmerku, ki je potreben za preprečevanje izgube kostne mase.
Fosavance alendronic acid and colecalciferol 
Fosavance alendronska kislina in holekalciferol
To avoid irritation of the oesophagus (the tube that leads from the mouth to the stomach), the patient should not lie down until after their first food of the day, which should be at least 30 minutes after taking the tablet. 
Da bi preprečili draženje požiralnika (cevke, ki vodi od ust do želodca), bolnica ne sme leči, dokler ne zaužije prvega dnevnega obroka hrane, kar pa ne sme biti prej kot 30 minut po zaužitju tablete.
What is the risk associated with Fosavance? 
Kakšna tveganja so povezana z zdravilom Fosavance?
Fosavance reduces the risk of fractures (broken bones) in the spine and the hip. 
Zdravilo Fosavance zmanjšuje tveganje za zlome kosti v hrbtenici in kolkih.
Fosavance must not be used in patients who have abnormalities of the oesophagus, who have hypocalcaemia (low blood calcium levels), or who cannot stand or sit upright for at least 30 minutes. 
Zdravila Fosavance ne smejo uporabljati bolnice z nepravilnostmi v požiralniku, bolnice s hipokalciemijo (nizkimi ravnmi kalcija v krvi) ali tiste, ki vsaj 30 minut ne morejo vzravnano stati ali sedeti.
For the full list of all side effects reported with Fosavance, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Fosavance, glejte navodilo za uporabo.
This study was extended in 652 patients for a further 24 weeks to compare the effects of continuing with Fosavance 70 mg/2,800 IU on its own or adding another 2,800 IU vitamin D3 (equivalent to using Fosavance 70 mg/5,600 IU). 
Ta študija je bila pri 652 bolnicah podaljšana za nadaljnjih 24 tednov, da bi primerjali učinke nadaljevanja zdravljenja samo z zdravilom Fosavance v odmerku 70 mg/2 800 i.e. z učinki dodajanja 2 800 i.e. vitamina D3 (kar je enakovredno uporabi zdravila Fosavance 70 mg/5 600 i.e.).
The most common side effects with Fosavance (seen between 1 and 10 patients in 100) are headache, abdominal pain (stomach ache), dyspepsia (heartburn), constipation, diarrhoea, flatulence (gas), 
Najpogostejši neželeni učinki zdravila Fosavance (opaženi pri 1 do 10 bolnikih od 100) so glavobol, bolečine v trebuhu, dispepsija (zgaga), zaprtje, driska, flatulenca (vetrovi), razjede požiralnika, disfagija (težave pri požiranju), napihnjen trebuh, refluks kisline in mišično-skeletne bolečine (bolečine v mišicah, kosteh in sklepih).
Why has Fosavance been approved? 
Zakaj je bilo zdravilo Fosavance odobreno?
To support the combination of alendronic acid and vitamin D3 in the same tablet, the company also carried out a study in 717 patients with osteoporosis, including 682 women who had been through the menopause, to show Fosavance's ability to increase vitamin D levels. 
V podporo uporabi kombinacije alendronske kisline in vitamina D3 v isti tableti in za pridobitev dokazov, da lahko zdravilo Fosavance poveča ravni vitamina D, je družba opravila študijo s 717 bolnicami z osteoporozo, ki je vključevala 682 žensk, ki so že prestale menopavzo.
Fosavance is a medicine that contains two active substances: alendronic acid and colecalciferol (vitamin D3). 
Fosavance je zdravilo, ki vsebuje dve zdravilni učinkovini: alendronsko kislino in holekalciferol (vitamin D3).
Fosavance contains two active substances: alendronic acid and colecalciferol (vitamin D3). 
Fosavance je vsebuje dve zdravilni učinkovini: alendronsko kislino in holekalciferol (vitamin D3).
Patients received either Fosavance 70 mg/2,800 IU or alendronic acid only once a week. 
Bolnice so enkrat tedensko prejemale bodisi zdravilo Fosavance 70 mg/2 800 i.e. bodisi le alendronsko kislino.
Fosavance (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of low vitamin D levels. 
Zdravilo Fosavance (ki vsebuje 2 800 ali 5 600 i.e. holekalciferola) se uporablja za zdravljenje osteoporoze (bolezni, ki povzroča krhkost kosti) pri ženskah po menopavzi, pri katerih obstaja tveganje za pomanjkanje vitamina D. Pri bolnicah, ki ne jemljejo dodatkov vitamina D se uporablja zdravilo Fosavance v odmerku 70 mg/5 600 i.e.
In the extension study, similar numbers of patients taking Fosavance 70 mg/2,800 IU and Fosavance 70 mg/5,600 IU had low vitamin D levels (below 6%), but the patients taking Fosavance 70 mg/5,600 IU had greater increases in vitamin D levels over the 24 weeks of the study. 
V podaljšani študiji je bilo število bolnic z nizkimi ravnmi vitamina D (pod 6 %) v skupini bolnic, ki so jemale zdravilo Fosavance 70 mg/2 800 i.e., podobno številu bolnic v skupini, ki je prejemala zdravilo Fosavance 70 mg/5 600 i.e., vendar pa so se pri bolnicah, ki so jemale zdravilo Fosavance 70 mg/5 600 i.e., v 24 tednih študije ravni vitamina D bolj povečale.
Patients should also take calcium supplements if they are not getting enough calcium from their diet. For more information, see the package leaflet. 
Jemati morajo tudi dodatke kalcija, če njegov vnos s prehrano ni zadosten.
What is Fosavance used for? 
Za kaj se zdravilo Fosavance uporablja?
How has Fosavance been studied? 
Kako je bilo zdravilo Fosavance raziskano?
How is Fosavance used? 
Kako se zdravilo Fosavance uporablja?
What is Fosavance? 
Kaj je zdravilo Fosavance?
How does Fosavance work? 
Kako zdravilo Fosavance deluje?
After 15 weeks, fewer patients had low vitamin D levels when they took Fosavance 70 mg/2,800 IU (11%) than when they took alendronic acid only (32%). 
Dodatne študije so pokazale, da lahko vključitev vitamina D3 in alendronske kisline v isto tableto poveča ravni vitamina D. Po 15 tednih zdravljenja je bil delež bolnic z nizko ravnijo vitamina D med bolnicami, zdravljenimi z zdravilom Fosavance 70 mg/2 800 i.e., nižji (11 %) kot pri tistih, ki so prejemale le alendronsko kislino (32 %).
the dose should be reduced gradually, over at least a week. 
mora nižanje odmerka potekati postopno in trajati najmanj en teden.
is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription. 
je na voljo v obliki kapsul (25, 50, 75, 100, 150, 200, 225 in 300 mg).
The maximum dose is 600 mg per day. 
Največji odmerek je 600 mg na dan.
is a medicine used to treat adults with the following conditions: 
je zdravilo, ki se uporablja za zdravljenje odraslih z naslednjimi boleznimi:
This reduces the activity of nerve cells in the brain and spinal cord that are involved in pain, epilepsy and anxiety. 
S tem se zmanjša dejavnost živčnih celic v možganih in hrbtenjači, ki so povezane z bolečino, epilepsijo in tesnobo.
contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Lyrica. 
To pomeni, da vsebuje enako zdravilno učinkovino in ima enak način delovanja kot „referenčno zdravilo“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilo Lyrica.
is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaka kot pri referenčnem zdravilu.
Doctors may choose lower doses in patients with kidney problems. 
Zdravniki lahko zmanjšajo odmerek pri bolnikih s težavami z ledvicami.
The active substance in Pregabalin Zentiva k.s., pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects. 
Zdravilna učinkovina v zdravilu Pregabalin Zentiva k.s., pregabalin, ima podobno strukturo kot telesu lastni živčni prenašalec („nevrotransmitor“) gama-aminomaslena kislina (GABA), vendar pa ima bistveno drugačne biološke učinke.
Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Zentiva k.s. 
Študije o koristih in tveganjih zdravilne učinkovine pri dovoljenih načinih uporabe so že bile izvedene z referenčnim zdravilom Lyrica, zato jih ni treba ponoviti za zdravilo Pregabalin Zentiva k.s.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Zentiva k.s. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pregabalin Zentiva k.s.
• neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with herpes zoster (shingles) or nerve disorders caused by diabetes, 
• nevropatsko bolečino (bolečino zaradi poškodbe živcev), vključno s periferno nevropatsko bolečino, kot se pojavlja pri bolnikih, ki imajo herpes zoster (pasovec) ali motnje živčevja, ki jih povzroča diabetes, in centralno nevropatsko bolečino, kot se pojavlja pri bolnikih s poškodbo hrbtenjače;
This is a summary of the European public assessment report (EPAR) for Pregabalin Zentiva k.s. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pregabalin Zentiva k.s.
As for every medicine, the company provided studies on the quality of Pregabalin Zentiva k.s. 
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Pregabalin Zentiva k.s.
What measures are being taken to ensure the safe and effective use of Pregabalin Zentiva k.s. 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pregabalin Zentiva k.s.
(epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment; 
• epilepsijo, pri čemer se uporablja kot „dodatek“ obstoječemu zdravljenju pri bolnikih s parcialnimi napadi (epileptičnimi napadi, ki se začnejo v določenem delu možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem;
For more information about treatment with Pregabalin Zentiva k.s., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
has been shown to have comparable quality and to be bioequivalent to Lyrica. 
primerljivo raven kakovosti kot zdravilo Lyrica ter da mu je biološko enakovredno.
What are the benefits and risks of Pregabalin Zentiva k.s. 
Kakšne so koristi in tveganja, povezani z zdravilom Pregabalin Zentiva k.s.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Zentiva k.s. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pregabalin Zentiva k.s.
For practical information about using Pregabalin Zentiva k.s., patients should read the package leaflet or contact their doctor or pharmacist. 
naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
When stopping treatment with Pregabalin Zentiva k.s. 
Pri prenehanju zdravljenja z zdravilom Pregabalin Zentiva k.s.
contains the active substance pregabalin. 
vsebuje zdravilno učinkovino pregabalin.
Other information about Pregabalin Zentiva k.s. 
Druge informacije o zdravilu Pregabalin Zentiva k.s.
The Committee recommended that Pregabalin Zentiva k.s. 
Priporočil je, da se zdravilo Pregabalin Zentiva k.s.
It is not intended to provide practical advice on how to use Pregabalin Zentiva k.s. 
Za praktične informacije o uporabi zdravila Pregabalin Zentiva k.s.
Why is Pregabalin Zentiva k.s. 
Zakaj je bilo zdravilo Pregabalin Zentiva k.s.
What is Pregabalin Zentiva k.s. 
Kaj je zdravilo Pregabalin Zentiva k.s.
The full EPAR for Pregabalin Zentiva k.s. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pregabalin Zentiva k.s.
Because Pregabalin Zentiva k.s. 
Ker je zdravilo Pregabalin Zentiva k.s.
How has Pregabalin Zentiva k.s. 
Kako se zdravilo Pregabalin Zentiva k.s.
To reduce administrative work, all response documents should be submitted as a single data package one year after the issue of the EC decision. 
Zaradi zmanjšanja administrativnega dela se morajo vsi odgovori predložiti v obliki enega podatkovnega paketa v enem letu po izdaji odločitve Evropske komisije.
The MAH commits to respond to a number of unresolved quality related issues by presenting relevant and adequate documents and data as outlined in the Letter of Undertaking dated 9 December 2009. 
Imetnik dovoljenja za promet z zdravilom se zavezuje, da bo odgovoril na številna nerešena vprašanja glede kakovosti s predložitvijo ustreznih in zadostnih dokumentov ter podatkov, kakor je predvideno v pismu o zavezi z dne 9. decembra 2009.
The National Competent Authorities, coordinated by the Reference Member State, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders: 
Pristojni nacionalni organi, ki jih usklajuje referenčna država članica, naj zagotovijo, da imetniki dovoljenja za promet z zdravilom izpolnijo naslednje pogoje:
This summary was last updated in April 2016. 
Povzetek je bil nazadnje posodobljen aprila 2016.
The full EPAR for Clynav can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila Clynav je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
In the future, if the fish are exposed to the virus, the immune system will be able to respond more quickly. 
Ob ponovni izpostavitvi ribe virusu v prihodnosti se bo imunski sistem tako hitreje odzval.
Direct contact should be avoided and protective equipment (for example protective gloves) should be worn when handling the medicine. 
Treba se je izogibati neposrednemu stiku in med ravnanjem z zdravilom uporabljati zaščitno opremo (na primer zaščitne rokavice).
This is a summary of the European public assessment report (EPAR) for Clynav. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clynav.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clynav's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Clynav večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The time for protection to develop following vaccination depends on the water temperature: protection starts within 399 degree days, calculated as mean water temperature in °C multiplied by number of days, for example 40 days at a water temperature of 10 °C. 
Čas do razvoja zaščite po cepljenju je odvisen od temperature vode: zaščita nastopi po 399 dnevnih stopinjah, kar se izračuna kot povprečna temperatura vode v °C, pomnožena s številom dni, na primer 40 dni pri temperaturi vode 10 °C.
Needle injuries at the site of injection are common following vaccination and can persist for at least 90 days. 
Poškodbe zaradi vboda z iglo na mestu injiciranja so po cepljenju pogoste in lahko trajajo najmanj 90 dni.
The most common side effects with Clynav (which may affect more than 1 in 10 fish) are short lived changes in swimming behaviour for up to two days, altered pigmentation (colouration) for up to seven days and lack of appetite for up to nine days. 
Najpogostejši neželeni učinki zdravila Clynav (ki se lahko pojavijo pri več kot 1 ribi od 10) so prehodne spremembe v načinu plavanja, ki trajajo do dva dni, spremenjena pigmentacija (obarvanje), ki traja do sedem dni, in pomanjkanje apetita, ki traja do devet dni.
The vaccine is given to anaesthetised fish as a single injection into epaxial muscle (muscle of the upper half of the fish) in the area to the front and side of the dorsal fin. 
Cepivo se daje anesteziranim ribam v obliki enkratne injekcije v epaksialno mišico (mišico na zgornji polovici ribe) v predel pred hrbtno plavutjo in ob njej.
The withdrawal period for fish from Atlantic salmon treated with Clynav is ‘zero' days, which means there is no mandatory waiting time. 
Karenca za atlantske losose, zdravljene z zdravilom Clynav, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
What are the risks associated with Clynav? 
Kakšna tveganja so povezana z zdravilom Clynav?
Clynav is a DNA vaccine. 
Zdravilo Clynav je DNK-cepivo.
Following artificial infection by co-habitation with infected salmon 29 days and 3 months after vaccination, fish vaccinated with Clynav had improved weight gain, reduced heart, pancreas and skeletal muscle lesions and reduced risk of death compared to fish injected with the dummy saline injection. 
Po umetni okužbi s sobivanjem z okuženimi lososi 29 dni in 3 mesece po cepljenju so imele ribe, cepljene z zdravilom Clynav, boljši prirast telesne mase, manj lezij na srcu, trebušni slinavki in skeletnih mišicah ter manjše tveganje za smrt v primerjavi z ribami, ki so prejele injekcijo fiziološke raztopine brez zdravilne učinkovine.
Other information about Clynav: 
Druge informacije o zdravilu Clynav
Pancreas disease in Atlantic salmon can lead to impaired daily weight gain, lesions of the heart, pancreas and skeletal muscle as well as death. 
Bolezen trebušne slinavke pri atlantskem lososu lahko privede do oslabljenega dnevnega prirasta telesne mase, lezij na srcu, trebušni slinavki in skeletnih mišicah ter smrti.
What benefits of Clynav have been shown in studies? 
Kakšne koristi je zdravilo Clynav izkazalo v študijah?
Protection lasts approximately three months after vaccination at average water temperature of 12 ±2 °C. 
Zaščita pri povprečni temperaturi vode 12 ±2 °C traja približno tri mesece po cepljenju.
The immune system recognises these virus proteins as ‘foreign' and makes defences against them. 
Imunski sistem virusne beljakovine prepozna kot „tujek“ in začne proti njim tvoriti protitelesa.
Clynav is a veterinary vaccine used in Atlantic salmon to protect them against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3). 
Clynav je cepivo za uporabo v veterinarski medicini, ki se uporablja pri atlantskem lososu za zaščito pred boleznijo trebušne slinavke, ki jo povzroča salmonidni alfavirus podtipa 3 (SAV3).
Six laboratory studies were conducted in fresh water and sea water to show how effective the vaccine was in protecting salmon from disease caused by SPDV. 
V sladki in morski vodi so opravili šest laboratorijskih študij, s katerimi so dokazovali učinkovitost cepiva pri zaščiti lososa pred boleznijo, ki jo povzroča SPDV.
What is Clynav and what is it used for? 
Kaj je zdravilo Clynav in za kaj se uporablja?
Vaccines work by ‘teaching' the immune system (the body's natural defences) 
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo“, kako naj se brani pred boleznijo.
The European Commission granted a marketing authorisation valid throughout the EU for Clynav on 
Evropska komisija je dovoljenje za promet z zdravilom Clynav, veljavno po vsej Evropski uniji, izdala
For the full list of all side effects reported with Clynav, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Clynav, glejte navodilo za uporabo.
In case of accidental needle stick or self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor. 
V primeru nenamernega vboda z iglo ali samoinjiciranja nemudoma poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko.
Why is Clynav approved? 
Zakaj je bilo zdravilo Clynav odobreno?
It is not intended to provide practical advice on how to use Clynav. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Clynav is available as a solution for injection and can only be obtained with a prescription. 
Zdravilo Clynav je na voljo v obliki raztopine za injiciranje, predpisovanje in izdaja zdravila pa je le na recept.
A main laboratory model study looked at the signs of pancreas disease in fish given Clynav compared with a dummy saline injection. 
V glavni laboratorijski modelni študiji so preučevali znake bolezni trebušne slinavke pri ribah, ki so prejele zdravilo Clynav, v primerjavi z injekcijo fiziološke raztopine brez zdravilne učinkovine.
For practical information about using Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za praktične informacije o uporabi zdravila Clynav naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For more information about treatment with Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za več informacij o zdravljenju z zdravilom Clynav naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
Clynav contains as active substance a DNA plasmid (a small piece of DNA) containing the genetic code for making salmon pancreas disease virus proteins. 
Zdravilo Clynav kot zdravilno učinkovino vsebuje plazmidno DNK (majhen del DNK), ki vsebuje genetski zapis za proizvodnjo beljakovin virusa bolezni trebušne slinavke pri lososu.
How does Clynav work? 
Kako zdravilo Clynav deluje?
Clynav salmon pancreas disease vaccine (recombinant DNA plasmid) 
Clynav cepivo za bolezen trebušne slinavke pri lososu (rekombinantna plazmidna DNK)
Clynav contains a DNA plasmid which, once injected into fish, will lead to the production of salmon pancreas disease virus (SPDV) proteins. 
Zdravilo Clynav vsebuje plazmidno DNK, ki po injiciranju v ribo sproži nastajanje beljakovin virusa bolezni trebušne slinavke pri lososu (SPDV).
How is Clynav used? 
Kako se zdravilo Clynav uporablja?
The fate of the remainder is unknown. 
Usoda preostanka ni znana.
This means that the risk that you develop a malignant disease in the future is slightly higher than for healthy people. 
To pomeni, da je tveganje, da se pri vas v prihodnje razvije maligna bolezen, nekoliko višje kot pri zdravih ljudeh.
Date of first authorisation: 14/04/2004 Date of last renewal: 27/03/2009 
Datum prve odobritve: 14/04/2004 Datum zadnjega podaljšanja: 27/03/2009